LOS ANGELES, Calif. | June 23, 2026
Armata Pharmaceuticals has received an additional $2.5 million in non-dilutive funding from the U.S. Department of Defense (DoD) to support the continued clinical development of AP-SA02, the company’s lead bacteriophage therapy candidate for the treatment of complicated Staphylococcus aureus bacteremia (SAB). The latest award increases total DoD funding for the program to $28.7 million, with the new investment focused on supporting Phase 3 clinical trial readiness. The funding is being provided through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Command (NMRC) under the Naval Advanced Medical Development (NAMD) program, reinforcing ongoing federal support for innovative therapies targeting antibiotic-resistant bacterial infections.
AP-SA02 Targets Drug-Resistant Staphylococcus aureus Infections
AP-SA02 is a fixed multi-phage cocktail developed as an adjunctive treatment for complicated Staphylococcus aureus bacteremia, including infections caused by both methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). Unlike conventional antibiotics, bacteriophage therapy uses naturally occurring viruses that specifically infect and destroy harmful bacteria, offering a promising strategy against the growing threat of antimicrobial resistance (AMR). The investigational therapy has already received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the U.S. Food and Drug Administration (FDA), highlighting its potential to address a serious unmet medical need in patients suffering from severe bloodstream infections.
Funding Supports Planned Phase 3 Clinical Development
The newly awarded $2.5 million will support critical activities required to prepare AP-SA02 for its planned Phase 3 superiority trial, which Armata Pharmaceuticals expects to initiate during the second half of 2026. The company’s earlier Phase 1b/2a diSArm clinical trial (NCT05184764) demonstrated positive safety and efficacy findings when AP-SA02 was administered intravenously alongside the best available antibiotic therapy in adults with complicated Staphylococcus aureus bacteremia. Results from the study were presented during a late-breaking oral presentation at IDWeek 2025, providing encouraging evidence for advancing the therapy into larger confirmatory clinical studies. According to the company, investigators across multiple U.S. clinical sites have expressed strong interest in participating in the upcoming Phase 3 program.
Advertisement
Phage Therapy Gains Momentum Against Antimicrobial Resistance
With antimicrobial resistance continuing to pose a major global healthcare challenge, Armata Pharmaceuticals believes bacteriophage-based therapeutics could become an important addition to existing antibiotic treatment strategies. Company leadership emphasized that continued Department of Defense support reflects the strategic importance of advancing innovative therapies capable of addressing infections affecting both military personnel and the broader civilian population. Beyond AP-SA02, Armata is developing a broader pipeline of natural and synthetic bacteriophage therapies targeting difficult-to-treat pathogens, including Pseudomonas aeruginosa and other clinically significant bacteria. Supported by in-house current Good Manufacturing Practice (cGMP) manufacturing capabilities, the company aims to accelerate the development and future commercialization of precision phage therapies designed to combat the growing burden of drug-resistant bacterial infections.
Source: Armata Pharmaceuticals press release
